SEC Company Response from ELITE PHARMACEUTICALS (ELTP) — Jun 2, 2017
ELITE PHARMACEUTICALS INC /NV/ (ELTP) (CIK 0001053369)
Date: June 2, 2017 · CIK: 0001053369 · Accession: 0001144204-17-030794
AI Filing Summary & Sentiment
File numbers found in text: 333-217866
Show Raw Text
CORRESP
1
filename1.htm
ELITE PHARMACEUTICALS, INC.
165 Ludlow Avenue
Northvale, NJ 07647
June 2, 2017
Suzanne Hayes, Esq.
Assistant Director
Division of Corporation Finance
Office of Healthcare & Insurance
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20002
Re: Elite Pharmaceuticals, Inc.
Registration Statement on Form S-3
(SEC filing No. 333-217866)
Acceleration Request
Requested Date: June 5, 2017
Requested Time: 4:00 P.M. Eastern
Time
Dear Ms. Hayes:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Elite Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration
Statement on Form S-3 (File No. 333-217866) (the “Registration Statement”) be declared effective at the “Requested
Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request
via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration
Statement has been declared effective, please orally confirm that event with our counsel, Richard Feiner, Esq., by calling him
at (646) 822-1170.
Very truly yours,
ELITE PHARMACEUTICALS, INC.
By:
/s/ Carter Ward
Carter Ward,
Chief Financial Officer
cc: Richard Feiner, Esq.